Global Prostate Cancer Diagnostics Market, By Product Type (Instruments, Reagents & Consumables, Accessories), Diagnostics Type (Preliminary Screening Tests, Confirmatory Tests), Age Group (Adult, Pediatric, Geriatrics), Type (Prostatic Adenocarcinoma, Small Cell Carcinoma, Others), Stage (Localized Prostate Cancer, Recurrent/Advanced Prostate Cancer, Castration-Resistant Prostate Cancer (Metastatic, Non-Metastatic), Sample Type (Blood, Tissue, Urine, Others), End Users (Independent Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Direct Tender, Retail Sales) - Industry Trends & Forecast to 2031.
Prostate Cancer Diagnostics Market Analysis and Size
Prostate cancer diagnostics play an important role in the early detection and efficient management of the disease. It includes the usage of instruments, reagents & consumables, and accessories. The PSA testing is the most common preliminary diagnosis of prostate cancer which may or may not require confirmatory tests for detection of the cancer.
The use of prostate cancer diagnostics has several benefits such as it helps in early detection of prostate cancer at localized stages and thereby aids the people to achieve efficient health management. The use of prostate cancer diagnostics is gaining popularity across the globe and it is particularly in emerging markets with increasing standards of healthcare.
Data Bridge Market Research analyzes that the global prostate cancer diagnostics market which was USD 4,196.09 million in 2023, is likely to reach USD 9.327.01 million by 2031, and is expected to undergo a CAGR of 10.5% during the forecast period. The “adults” accounts for the largest market share in the age group segment in the market due to the higher prevalence of cancer in adult males. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Prostate Cancer Diagnostics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product Type (Instruments, Reagents & Consumables, Accessories), Diagnostics Type (Preliminary Screening Tests, Confirmatory Tests), Age Group (Adult, Pediatric, Geriatrics), Type (Prostatic Adenocarcinoma, Small Cell Carcinoma, Others), Stage (Localized Prostate Cancer, Recurrent/Advanced Prostate Cancer, Castration-Resistant Prostate Cancer (Metastatic, Non-Metastatic), Sample Type (Blood, Tissue, Urine, Others), End Users (Independent Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Direct Tender, Retail Sales)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Belgium, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa.
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd (Switzerland), ACON Laboratories, Inc. (U.S.), HUMASIS (South Korea), Teco Diagnostics (U.S.), Hologic Inc. (U.S.), Accuquik Test Kits (U.S.), MDxHealthcare (Belgium), Abbott (U.S.), Siemens Healthcare GmbH (Germany), OPKO Health Inc. (U.S.), Myriad Genetics, Inc. (U.S.), DiaSorin S.p.A (Italy), Beckman Coulter, Inc. (a subsidiary of Danaher) (U.S.), Genomic Health, Inc. (a subsidiary of Exact Sciences Corporation) (U.S.), bioMérieux SA (France), Metamark Genetics, Inc. (U.S.), Prostatype Genomics (Switzerland), Fujirebio (Belgium), Proteomedix (Switzerland), Eurolyser Diagnostica GmbH (Austria)
|
|
Market Opportunities
|
|
Market Definition
Prostate cancer diagnosis involves a combination of medical history assessment, physical examination, and specific diagnostic tests. The initial steps often include a digital rectal exam (DRE) to assess the prostate gland for abnormalities. Blood tests, such as the prostate-specific antigen (PSA) test, measure elevated levels of a protein associated with prostate conditions, including cancer. Imaging studies like ultrasound, magnetic resonance imaging (MRI), or computed tomography (CT) scans may be employed to visualize the prostate and surrounding tissues for signs of cancer. A biopsy, typically guided by imaging, involves the removal of tissue samples from the prostate for laboratory analysis to confirm the presence of cancerous cells and determine the cancer's aggressiveness. The combined results of these assessments help physicians formulate an accurate diagnosis and determine an appropriate course of treatment for the patient.
Global Prostate Cancer Diagnostics Market Dynamics
Drivers
- Increasing Aging Population
The demographic shift towards an aging population is a significant driver for the prostate cancer diagnostics market. Prostate cancer predominantly affects older men, and as the proportion of elderly individuals rises globally, there is a natural increase in the number of people at risk for prostate cancer. The elderly demographic often undergoes routine screenings and diagnostic tests, contributing to the overall demand for prostate cancer diagnostics.
- Rising Incidence of Prostate Cancer
The incidence of prostate cancer has been steadily increasing, making it a major driver for diagnostic market growth. Factors such as lifestyle changes, environmental influences, and genetic predispositions contribute to the higher occurrence of prostate cancer cases. The heightened awareness of the disease and the importance of early detection have led to more individuals seeking diagnostic evaluations, further fuelling the demand for advanced and accurate diagnostic tools in the market.
Opportunities
- Advancements in Biomarker Research
Ongoing exploration of new biomarkers associated with prostate cancer, such as genetic mutations, circulating tumor cells, and specific proteins, creates opportunities for the development of highly sensitive and specific diagnostic tests. As researchers uncover more nuanced details about the molecular signatures of prostate cancer, diagnostic companies can leverage this knowledge to enhance the precision and reliability of diagnostic tools, ultimately improving early detection rates and patient outcomes.
- Focus on Personalized Medicine
The increasing emphasis on personalized medicine in prostate cancer diagnostics presents an opportunity to tailor diagnostic approaches based on individual patient characteristics. Integrating genetic profiling, molecular analysis, and patient-specific factors allows for a more targeted and effective diagnostic strategy. This personalized approach not only enhances the accuracy of prostate cancer diagnosis but also opens avenues for the development of customized treatment plans, aligning with the broader trend in healthcare towards more individualized and patient-centered care.
Restraints/Challenges
- Limited Specificity of Biomarkers
The challenge lies in the fact that some biomarkers used in prostate cancer diagnostics may lack the specificity needed to accurately distinguish between benign conditions and aggressive forms of the disease. This limitation can result in false-positive results, leading to unnecessary invasive procedures and overtreatment. Improving the specificity of biomarkers is crucial for enhancing the precision of diagnostic tests and ensuring more informed clinical decision-making.
- Invasive Nature of Diagnostic Procedures
Invasive diagnostic procedures, particularly prostate biopsies, pose a significant challenge due to associated discomfort, potential side effects, and the risk of infection. Patient apprehension and reluctance to undergo these procedures can result in delayed or avoided diagnostic evaluations, potentially leading to missed opportunities for early cancer detection. Developing less invasive or non-invasive diagnostic alternatives is essential to encourage broader patient participation and improve the overall patient experience in prostate cancer diagnostics.
This prostate cancer diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the prostate cancer diagnostics Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In October, 2020 Siemens Healthcare GmbH announced that they have launched Biograph Vision Quadra Extended Axial FoV PET/CT Scanner. This scanner is the industry’s most sensitive extended field view scanner designed for clinical and research purposes. The product is of high clinical use and will increase the demand for cancer diagnostic procedure and will increase the revenue for the company
- In March, 2020 DiaSorin S.p.A and TTP plc, a leading independent technology and product development company announced that they have signed an exclusive licensing and technology transfer agreement under which DiaSorin will gain access to TTP’s Puckdx TM, a flexible and low-cost platform for the automation of sample-to-answer diagnostic assays. This will increase the advancement in diagnostic business profile for the company and will help in future business development
Global Prostate Cancer Diagnostics Market Scope
The prostate cancer diagnostics market is segmented on the basis of product type, diagnostics type, age group, type, stage, sample type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Instruments
- Reagents & Consumables
- Accessories
Diagnostics Type
- Preliminary Screening Tests
- Confirmatory Tests
Age Group
- Adult
- Pediatric
- Geriatrics
Type
- Prostatic Adenocarcinoma
- Small Cell Carcinoma
- Others
Stage
- Localized Prostate Cancer
- Recurrent/Advanced Prostate Cancer
- Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic)
Sample Type
- Blood
- Tissue
- Urine
- Others
End User
- Independent Diagnostic Laboratories
- Hospitals
- Cancer Research Institutes
- Clinics
- Ambulatory Surgical Centers
- Others
Distribution Channel
- Direct Tender
- Retail Sales
Global Prostate Cancer Diagnostics Market Regional Analysis/Insights
The prostate cancer diagnostics market is analyzed and market size insights and trends are provided by product type, diagnostics type, age group, type, stage, sample type, end user and distribution channel. as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, South Africa, U.A.E., Israel, Egypt, and rest of Middle East and Africa.
North America is expected to dominate the market and due to higher healthcare expenditure in the region and well equipped healthcare facilities to perform prostate cancer diagnositc tests.
Asia-Pacific is expected to grow with a highest CAGR in the forecast period due to rising prevalence of prostate cancer.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The Prostate cancer diagnostics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Prostate cancer diagnostics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Prostate cancer diagnostics market. The data is available for historic period 2010-2020.
Competitive Landscape and Global Prostate Cancer Diagnostics Market Share Analysis
The prostate cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to prostate cancer diagnostics market.
Some of the major players operating in the prostate cancer diagnostics market are:
- F. Hoffmann-La Roche Ltd (Switzerland)
- ACON Laboratories, Inc. (U.S.)
- HUMASIS (South Korea)
- Teco Diagnostics (U.S.)
- Hologic Inc. (U.S.)
- Accuquik Test Kits (U.S.)
- MDxHealthcare (Belgium)
- Abbott (U.S.)
- Siemens Healthcare GmbH (Germany)
- OPKO Health Inc. (U.S.)
- Myriad Genetics, Inc. (U.S.)
- DiaSorin S.p.A (Italy)
- Beckman Coulter, Inc. (a subsidiary of Danaher) (U.S.)
- Genomic Health, Inc. (a subsidiary of Exact Sciences Corporation) (U.S.)
- bioMérieux SA (France)
- Metamark Genetics, Inc. (U.S.)
- Prostatype Genomics (Switzerland)
- Fujirebio (Belgium)
- Proteomedix (Switzerland)
- Eurolyser Diagnostica GmbH (Austria)
SKU-